ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1048

Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens

Masatoshi Hayashi1, Hiroyuki Matsubara2, Kei Funamura1, Masataka Maeda1 and Toshihisa Kanamono1, 1Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, 2Orthopaedics, Hekinan municipal hospital, Hekinann, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Efficient, pharmacists and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) need to take lifelong oral or injectable medication to alleviate their symptoms and prevent disease progression. However, some patients may not adhere or poorly adhere to treatment and have poor understanding of biological agents. Poor or no adherence may be attributed to the following factors: complex regimen for medications, such as methotrexate (MTX), difficulty in self-administration of injectables due to hand deformities, and forgetfulness due to dementia. This study aimed at determining the effect of educating visiting pharmacists regarding administration of oral medication and injectables for patients with RA who poorly adhere to treatment regimens.

Methods: A prospective analysis was performed by enrolling 21 patients with RA who were treated with different types of medication, including self-injectable biological agents. Two cases were excluded because one had been added on subcutaneous tocilizumab and the other on MTX with increased dosage. The remaining 19 cases did not have any change in their treatment, including dosage or intervals between drug administration, just before and after the pharmacist visit. Baseline characteristics, such as age, Steinblocker Stage and Class, disease duration, use of biological agents, use of MTX and its dosage, use of prednisolone (PSL) and its dosage, presence of dementia, and living or not living alone, were assessed. DAS28-ESR, SDAI and CDAI as markers of RA disease activity were evaluated just before and after the pharmacist visit.

Results: Mean ± SD were as follows: age (years), 74.4 ± 6.1; Stage I, 1; II, 4; III, 6; IV, 8; Class 1, 0; 2, 7; 3, 8; 4, 4; disease duration (months), 144.2 ± 114.5; use of biological agents; 36.8%; use of MTX and its dosage (mg/week), 84.2% and 6.6 ± 2.7; use of PSL and its dosage (mg/day), 47.4% and 4.4 ± 1.2; presence of dementia, 10.5%; living alone, 42.1%. The mean values of DAS28-ESR, SDAI, and CDAI just before and after the pharmacist visit showed improvements; they were 3.56 ± 1.46 and 3.12 ± 1.16 (p = 0.084), 7.99 ± 6.88 and 4.39 ± 3.47 (p = 0.0176), and 6.85 ± 5.74 and 3.90 ± 3.18 (p = 0.0148), respectively. All patients reported satisfaction with the overall effectiveness of the care.

Conclusion: Adherence to treatment in patients with RA may decline with increasing age. For such patients, education regarding oral and injectable medication may be useful in controlling RA activity and avoiding any adverse effects due to consumption of wrong medication. This finding is important for better and safer management of patients with RA in the ageing communities in Japan and other developed countries.


Disclosure: M. Hayashi, None; H. Matsubara, None; K. Funamura, None; M. Maeda, None; T. Kanamono, None.

To cite this abstract in AMA style:

Hayashi M, Matsubara H, Funamura K, Maeda M, Kanamono T. Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-educating-visiting-pharmacists-regarding-drug-administration-for-patients-with-rheumatoid-arthritis-who-poorly-adhere-to-treatment-regimens/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-educating-visiting-pharmacists-regarding-drug-administration-for-patients-with-rheumatoid-arthritis-who-poorly-adhere-to-treatment-regimens/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology